- Home
- NVRO vs BCTXW Comparison
NVRO vs BCTXW Comparison
Compare NVRO & BCTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRO
- BCTXW
- Stock Information
- Founded
- NVRO 2006
- BCTXW N/A
- Country
- NVRO United States
- BCTXW Canada
- Employees
- NVRO N/A
- BCTXW 12
- Industry
- NVRO Medical/Dental Instruments
- BCTXW Biotechnology: Pharmaceutical Preparations
- Sector
- NVRO Health Care
- BCTXW Health Care
- Exchange
- NVRO Nasdaq
- BCTXW Nasdaq
- Market Cap
- NVRO 134.5M
- BCTXW N/A
- IPO Year
- NVRO 2014
- BCTXW N/A
- Fundamental
- Price
- NVRO $3.69
- BCTXW $0.25
- Analyst Decision
- NVRO Hold
- BCTXW
- Analyst Count
- NVRO 14
- BCTXW 0
- Target Price
- NVRO $7.97
- BCTXW N/A
- AVG Volume (30 Days)
- NVRO 416.5K
- BCTXW N/A
- Earning Date
- NVRO 02-19-2025
- BCTXW N/A
- Dividend Yield
- NVRO N/A
- BCTXW N/A
- EPS Growth
- NVRO N/A
- BCTXW N/A
- EPS
- NVRO N/A
- BCTXW N/A
- Revenue
- NVRO $419,146,000.00
- BCTXW N/A
- Revenue This Year
- NVRO N/A
- BCTXW N/A
- Revenue Next Year
- NVRO $0.65
- BCTXW N/A
- P/E Ratio
- NVRO N/A
- BCTXW N/A
- Revenue Growth
- NVRO N/A
- BCTXW N/A
- 52 Week Low
- NVRO $3.52
- BCTXW N/A
- 52 Week High
- NVRO $21.74
- BCTXW N/A
- Technical
- Relative Strength Index (RSI)
- NVRO 43.89
- BCTXW N/A
- Support Level
- NVRO $3.60
- BCTXW N/A
- Resistance Level
- NVRO $3.90
- BCTXW N/A
- Average True Range (ATR)
- NVRO 0.28
- BCTXW 0.00
- MACD
- NVRO 0.01
- BCTXW 0.00
- Stochastic Oscillator
- NVRO 39.56
- BCTXW 0.00
About NVRO Nevro Corp.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
About BCTXW BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.